About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
P
MANIFEST-2 Study: Pelabresib With Ruxolitinib for JAKi-Naïve Patients With Myelofibrosis
By
Prithviraj Bose
12 Videos
0 views
April 22, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Recommended
AUTOPLAY
ON
Related
Newest
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in Myeloproliferative Neoplasms
Feat.
E. Hexner
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
18:42
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
Feat.
A. Goldberg
24:48
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
Feat.
R. Rampal
08:11
Krisstina Gowin
Counseling Patients With Newly Diagnosed PV or ET
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
12:18
Fred Hutchinson Cancer Center
Management of MPNs for the Community Oncologist
Feat.
H. Deeg
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
06:51
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…
Feat.
D. Tremblay
29:17
UChicago Medicine
Overview of Recent Updates in MPNs and MDS
Feat.
S. Kosuri
11:03
Moffitt Cancer Center
Current Treatment Landscape of JAK Inhibitors in MF
Feat.
A. Kuykendall
12:07
Douglas Tremblay
Monitoring Patients With MF: When to Switch Treatment
15:31
Icahn School of Medicine at Mount Sinai
Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway
Feat.
M. Kremyanskaya
